





Overview


- Normal Growth and Physical Development
- Anticipatory Guidance/Health Supervision
- Common Screening Tests
- Immunizations
- Child Abuse
- Common Problems in General Pediatrics
- Ethics for Primary Care


3




















 Question 1


 How soon does an infant regain birth weight?


 A. 10 to 14 days


 B. 4 to 7 days


 C. 3 to 4 days


 D. An infant should not lose weight after birth























	r Seats	General Guidelines	
Age Group Infants & toddlers	Type of Seat Rear-facing—only Rear-facing convertible	All infants and toddlers should ride in a rear-facing seat until they reach the highest weight or height allowed by the car seat's manufacturer. Most convertible seats have limits that will permit children to ride rear-facing for 2 years or more.	
Toddlers & preschoolers	Convertible Forward-facing with harness	Children who have outgrown the rear-facing weight or height limit for their convertible seat should use a forward-facing seat with a harness for as long as possible, up to the highest weight or height allowed by their car safety seat manufacturer.	
School-aged children	Booster seats	All children whose weight or height exceeds the forward-facing limit for their car safety seat should use a belt-positioning booster seat until the vehicle seat belt fits properly, typically when they have reached 4 feet 9 inches in height and are 8 through 12 years of age. All children younger than 13 should ride in the back seat.	
Older children	Seat belts	When children are old enough and large enough for the vehicle seat belt to fit them correctly, they should always use lap and shoulder seat belts for the best protection. All children younger than 13 years should ride in the back seat.	





















































Conductive Hearing Loss	Sensorineural Hearing Loss
<u>Congenital</u>	
Microtia/atresia	Genetic disorders (syndromic, connexin 26,
Tympanic membrane abnormalities	mitochondrial)
Ossicular malformations	In utero infections (cytomegalovirus, measles, mumps, rubella, varicella, syphilis)
	Anatomic abnormalities of the cochlea or temporal bone
	Exposure to ototoxic drugs during pregnancy (alcohol, isotretinoin, cisplatinum)
	Hyperbilirubinemia
Acquired	
Infection (acute otitis media, otitis externa, ossicular erosion)	Infections (bacterial meningitis, measles, mumps, rubella, Lyme disease)
Otitis media with effusion	Trauma (physical or acoustic)
Foreign body (including cerumen)	Radiation therapy for head and neck tumors
Cholesteatoma	Neurodegenerative or demyelinating disorders
Trauma (ossicular disruption, tympanic membrane perforation)	(Alport, Cogan syndromes)









л	1
4	т


► B	lood Pressure (BP)			
Ai	nnually after 3 years				
	efore age 3 years, Bl ardiovascular conditi	P should be obtained ion)	if risk is present (I	renal or	
SE	everal days		5	period of at least	
► H	igh normal BP (90-95 TN is a blood pressu		ercentile and age)		
► H	igh normal BP (90-95 TN is a blood pressur	re over 95%	AAP 2017 for Children	≥13 y	_
► H	igh normal BP (90-95 TN is a blood pressu	re over 95%	ercentile and age)		
► H	igh normal BP (90-95 TN is a blood pressur AAP 2017 for Children 3 Classification	re over 95% 1-13 y SBP/DBP Percentile	AAP 2017 for Children Classification	≥13 y Absolute Threshold	
► H	igh normal BP (90-95 TN is a blood pressur AAP 2017 for Children : Classification Normal	re over 95% 1-13 y SBP/DBP Percentile <90th ≥90th to <95th Or 120/80 mm Hg to <95th (whichever is	AAP 2017 for Children Classification Normal	≥13 y Absolute Threshold <120/<80mmHg 120/<80 to	




























	Minimum		Persons aged 4 months through 6 years Minimum Interval Between Doses				
Vaccine	Age for Dose 1	Dose 1 to dose 2					
Hepatitis B ^r	Birth	4 weeks	8 weeks and at least 16 weeks after first dose; minimum age for the final dose is 24 weeks				
Rotavirus ²	6 weeks	4 weeks	4 weeks				
Diphtheria, tetanus, & acellular pertussis 3	6 weeks	4 weeks	4 weeks	6 months	6 months ²		
Haemophilus influenzee type b ^s	6 weeks	4 weeks if first dose administered at younger than age 12 months first dose administered at age 15 months No further doses needed if first dose administered at age 15 months or older	4 works/of fournet age is younger han 10 months and finat 8 works/or and use 12 months through 50 months data 8 works and use 12 months through 50 months rays final 4 months for a second second second second second second 8 months for a second second second second second second 1 months for a second second second second second second 1 months for a second second second second second second 1 months for a second second second second second second 1 months for a second second second second second second 1 months for a second	8 weeks (as final dose) This dose only necessary for children aged 12 through 58 months who received 3 (PR-P) dose before age 12 months and started the primary series before age 7 months			
Pneumococcal ^s	6 weeks	4 weeks if first dose administered at younger than age 28 weeks (as final dose for healthy children) if first dose administered at ge 12 months or older No further doses needed for healthy children if first dose administered at ge 24 months or older	4 weeks if current age is younger than 12 months 8 weeks (as final does for healthy children) if current age is 12 months or older No further does mended for healthy children if previous dose administered at age 24 months or older	B weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age			
Inactivated poliovirus7	6 weeks	4 weeks ⁷	4 weeks ⁷	6 months ⁷ minimum age 4 years for final dose			
Meningococcal ¹³	6 weeks	8 weeks ¹²	See footnote 13	See footnote 13			
Measles, mumps, rubella ⁹	12 months	4 weeks					
Varicella ¹⁰	12 months	3 months					
Hepatitis A [#]	12 months	6 months					
			Persons aged 7 through 18 years				
Tetanus, diphtheria; tetanus, diphtheria, & acellular pertussis	7 years ⁴	4 weeks	4 weeks if first dose of DTaP/DT administered at younger than age 12 months 6 months if first dose of DTaP/DT administered at age 12 months or older and then no further doses needed for catch-up	6 months if first dose of DTaP/DT administered at younger than age 12 months			
Human papillomavirus ¹²	9 years		Routine dosing intervals are recommended ¹²				
Hepatitis A ¹¹	12 months	6 months					
Hepatitis B ¹	Birth	4 weeks	8 weeks (and at least 16 weeks after first dose)				
Inactivated poliovirus7	6 weeks	4 weeks	4 weeks ⁷	6 months ⁷			
Meningococcal ¹³	6 weeks	8 weeks ¹²					
Measles, mumps, rubella ^s	12 months	4 weeks					
Varicella ¹⁰	12 months	3 months if person is younger than age 13 years 4 weeks if person is aged 13 years or older					
NOTE: The above	recomme	ndations must be read along with the foo	otnotes of this schedule.				



























MMR


- Measles-Mumps-Rubella (MMR)
- Live attenuated vaccine
- > 2 dose series given at 12-15 months and at 4-6 years
- Catch-up: 2 doses at least 4 weeks apart
- If given at <12 months old, needs to be repeated due to lack of immunogenicity
- Can be given as early as 6 months, but must be revaccinated at 12 months of age
- During an outbreak, MMR given within 72 hours of exposure to measles may provide some protection and is preferred to immune globulin




































































































Orbital vs	Periorbita	al Cellulitis
Clinical features of preseptal and orbital cellulit		
Clinical feature	Preseptal cellulitis	Orbital cellulitis
Eyelid swelling with or without erythema	Yes	Yes
Eye pain/tenderness	May be present	Yes; may cause deep eye pain
Pain with eye movements	No	Yes
Proptosis	No	Usually, but may be subtle
Ophthalmoplegia +/- diplopia	No	May be present
Vision impairment	No	May be present*
Chemosis	Rarely present	May be present
Fever	May be present	Usually present
Leukocytosis	May be present	May be present



97

